Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Gary A. Lyons sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, October 7th. The shares were sold at an average price of $105.06, for a total value of $525,300.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
NASDAQ NBIX opened at $103.65 on Thursday. The firm has a market capitalization of $9.80 billion, a P/E ratio of 27.86 and a beta of 0.73. The business has a fifty day simple moving average of $95.18 and a 200 day simple moving average of $95.74. Neurocrine Biosciences, Inc. has a 12 month low of $84.77 and a 12 month high of $120.27. The company has a current ratio of 5.21, a quick ratio of 5.08 and a debt-to-equity ratio of 0.26.
Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Monday, August 2nd. The company reported $0.43 earnings per share for the quarter, missing the consensus estimate of $0.52 by ($0.09). The firm had revenue of $288.90 million for the quarter, compared to the consensus estimate of $274.47 million. Neurocrine Biosciences had a return on equity of 33.04% and a net margin of 35.34%. As a group, sell-side analysts predict that Neurocrine Biosciences, Inc. will post 1.89 EPS for the current fiscal year.
A number of equities analysts have issued reports on NBIX shares. Needham & Company LLC started coverage on Neurocrine Biosciences in a report on Wednesday, September 22nd. They set a “hold” rating on the stock. Zacks Investment Research upgraded Neurocrine Biosciences from a “hold” rating to a “buy” rating and set a $115.00 price target on the stock in a report on Friday, October 8th. Morgan Stanley lowered their target price on Neurocrine Biosciences from $116.00 to $110.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 4th. HC Wainwright reaffirmed a “buy” rating on shares of Neurocrine Biosciences in a research report on Thursday, September 30th. Finally, Canaccord Genuity lowered Neurocrine Biosciences from a “buy” rating to a “hold” rating and lowered their target price for the stock from $122.00 to $108.00 in a research report on Friday, August 6th. Six investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $120.27.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is a neuroscience-focused, biopharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The firm’s product includes INGREZZA. The company was founded by Kevin C. Gorman and Wylie W.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.